These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25831650)

  • 1. Comparison of hypoglycaemia episodes in people with type-2 diabetes fasting in Ramazan, treated with vildaglipton or sulphonylurea: results of the Pakistani cohort of the VIRTUE study.
    Mahar SA; Hasan MI; Khan MI; Fawwad A; Hussain S; Maheshwary N; Kumar K; Siddiqi A; Khan MA
    J Pak Med Assoc; 2014 Nov; 64(11):1297-302. PubMed ID: 25831650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during Ramadan.
    Hanif W; Malik W; Hassanein M; Kamal A; Geransar P; Andrews C; Azam M; Barnett AH
    Curr Med Res Opin; 2013 Jul; 29(7):807-11. PubMed ID: 23659561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study.
    Al-Arouj M; Hassoun AA; Medlej R; Pathan MF; Shaltout I; Chawla MS; Hristoskova S; Ditommaso S; Kadwa MY
    Int J Clin Pract; 2013 Oct; 67(10):957-63. PubMed ID: 24001317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of vildagliptin relative to sulfonylurea as dual therapy with metformin (or as monotherapy) in Muslim patients with type 2 diabetes fasting during Ramadan in the Middle East: the VIRTUE study.
    Hassoun AA; Al-Arouj M; Ibrahim M
    Curr Med Res Opin; 2017 Jan; 33(1):161-167. PubMed ID: 27684469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study.
    Hassanein M; Hanif W; Malik W; Kamal A; Geransar P; Lister N; Andrews C; Barnett A
    Curr Med Res Opin; 2011 Jul; 27(7):1367-74. PubMed ID: 21568833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.
    Göke R; Gruenberger JB; Bader G; Dworak M
    Curr Med Res Opin; 2014 May; 30(5):785-9. PubMed ID: 24328429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
    Lukashevich V; Del Prato S; Araga M; Kothny W
    Diabetes Obes Metab; 2014 May; 16(5):403-9. PubMed ID: 24199686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study.
    Hassanein M; Abdallah K; Schweizer A
    Vasc Health Risk Manag; 2014; 10():319-26. PubMed ID: 24920915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
    Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S
    Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus.
    Yang W; Xing X; Lv X; Li Y; Ma J; Yuan G; Sun F; Wang W; Woloschak M; Lukashevich V; Kozlovski P; Kothny W;
    J Diabetes; 2015 Mar; 7(2):174-81. PubMed ID: 24823599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translating science into clinical practice: focus on vildagliptin in combination with metformin.
    Barnett AH
    Diabetes Obes Metab; 2009 May; 11 Suppl 2():18-26. PubMed ID: 19385980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan.
    Devendra D; Gohel B; Bravis V; Hui E; Salih S; Mehar S; Hassanein M
    Int J Clin Pract; 2009 Oct; 63(10):1446-50. PubMed ID: 19678856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.
    Derosa G; Bonaventura A; Bianchi L; Romano D; Fogari E; D'Angelo A; Maffioli P
    Metabolism; 2014 Jul; 63(7):957-67. PubMed ID: 24874591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials.
    Cai L; Cai Y; Lu ZJ; Zhang Y; Liu P
    J Clin Pharm Ther; 2012 Aug; 37(4):386-98. PubMed ID: 22191695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.
    Rosenstock J; Kim SW; Baron MA; Camisasca RP; Cressier F; Couturier A; Dejager S
    Diabetes Obes Metab; 2007 Mar; 9(2):175-85. PubMed ID: 17300593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
    Rosenstock J; Baron MA; Dejager S; Mills D; Schweizer A
    Diabetes Care; 2007 Feb; 30(2):217-23. PubMed ID: 17259484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vildagliptin versus insulin in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea: results from a randomized, 24 week study.
    Forst T; Koch C; Dworak M
    Curr Med Res Opin; 2015 Jun; 31(6):1079-84. PubMed ID: 25867771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
    Derosa G; Maffioli P; Ferrari I; Mereu R; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Salvadeo SA
    Horm Metab Res; 2010 Aug; 42(9):663-9. PubMed ID: 20560108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study.
    Bolli G; Dotta F; Rochotte E; Cohen SE
    Diabetes Obes Metab; 2008 Jan; 10(1):82-90. PubMed ID: 18034842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and effectiveness of non-insulin glucose-lowering agents in the treatment of people with type 2 diabetes who observe Ramadan: a systematic review and meta-analysis.
    Gray LJ; Dales J; Brady EM; Khunti K; Hanif W; Davies MJ
    Diabetes Obes Metab; 2015 Jul; 17(7):639-48. PubMed ID: 25777247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.